LogicBio IPO: Undervalued, But Phase 1/2 Clinical Trial Will Commence By The End Of 2019 [Seeking Alpha]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Seeking Alpha
Summary LogicBio ( LOGC ) seems cheap as compared to peers conducting similar research. The company is expected to have a market capitalization of $269 million, while the competitors have market capitalization of more than $318 million. Additionally, it is also beneficial that many institutional investors invested in LogicBio prior to the IPO. With that, investors should understand that the company is still at the preclinical stage of development. LogicBio seems a name for very long-term investors. Source: Prospectus The underwriters working on this deal are very relevant. The company hired some of the biggest names on Wall Street, which the market will appreciate. Take a look at the following list: Source: Prospectus Business Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio develops treatments for rare diseases using its proprietary platform GeneRide. Having demonstrated proof of concept of the company’s therapeuti
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth [Reuters]Reuters
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth [Yahoo! Finance]Yahoo! Finance
- Crispr Therapeutics: Now Is The Time To Buy [Seeking Alpha]Seeking Alpha
- Aspen Ideas: Health Announces Global Health Experts to Speak at Annual Summit [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/10/24 - Form SC
- CRSP's page on the SEC website